Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

06. Januar 2026 08:00 ET | Quelle: Heartflow, Inc.

Heartflow Plaque Analysis Now Covered by Aetna Insurance Plans Nationwide and for the Majority of Insured Lives in the U.S.

MOUNTAIN VIEW, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced Heartflow Plaque...
06. Januar 2026 08:00 ET | Quelle: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026

RADNOR, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and...
05. Januar 2026 16:05 ET | Quelle: Heartflow, Inc.

Heartflow to Participate in the 44th Annual J.P. Morgan Healthcare Conference

MOUNTAIN VIEW, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today...
22. Dezember 2025 06:38 ET | Quelle: Research and Markets

American Heart Association (AHA) Scientific Sessions Highlights Report 2025: Market Opportunities Lie in Novel Therapeutics Like Semaglutide, VK2735, SHR-1918, BacNav, and Satralizumab

Dublin, Dec. 22, 2025 (GLOBE NEWSWIRE) -- The "American Heart Association (AHA): Scientific Sessions 2025 Highlights" report has been added to ResearchAndMarkets.com's offering. AHA 2025 took...
19. Dezember 2025 16:00 ET | Quelle: Cytokinetics, Incorporated

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company’s First...
19. Dezember 2025 08:00 ET | Quelle: Esperion Therapeutics, Inc.

Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes

– Bempedoic Acid Highlighted by ACC for LDL-C Lowering in Patients with Peripheral Artery Disease and Diabetes Based on Proven Cardiovascular and Limb Benefits – ANN ARBOR, Mich., Dec. 19, 2025 ...
18. Dezember 2025 16:05 ET | Quelle: Heartflow, Inc.

Heartflow Plaque Analysis Now Supported by Scientific Statements From American College of Cardiology and American Heart Association for Personalized Management of Patients with Suspected CAD

MOUNTAIN VIEW, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), announced the American College of...
17. Dezember 2025 12:50 ET | Quelle: DeLorean AI

DeLorean AI Releases New Cardiovascular AI White Paper Showing Predictive AI Can Prevent Heart Failure and Cut Costs by Up to $350,000 Per Patient

Clinically validated platform delivers predictive precision, empowering clinicians with real-time visibility to reduce preventable complications and improve patient outcomes PALM BEACH, Fla., Dec. ...
17. Dezember 2025 07:30 ET | Quelle: Cytokinetics, Incorporated

Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

Approval Triggers Milestone Payment of $7.5 Million from Sanofi; Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on Net Sales in Greater China SOUTH SAN FRANCISCO,...
12. Dezember 2025 08:42 ET | Quelle: Cytokinetics, Incorporated

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the...

Vorherige Seite

Nächste Seite